"Hematologic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that act on blood and blood-forming organs and those that affect the hemostatic system.
| Descriptor ID |
D006401
|
| MeSH Number(s) |
D27.505.954.502
|
| Concept/Terms |
Hematologic Agents- Hematologic Agents
- Agents, Hematologic
- Hematological Agents
- Agents, Hematological
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Agents".
This graph shows the total number of publications written about "Hematologic Agents" by people in this website by year, and whether "Hematologic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematologic Agents" by people in Profiles.
-
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22; 390(8):723-735.
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
-
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. Clin Lymphoma Myeloma Leuk. 2018 08; 18(8):528-532.
-
Minimizing Blood Loss and Transfusions in Total Knee Arthroplasty. J Knee Surg. 2018 Aug; 31(7):594-599.
-
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913.
-
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw. 2016 12; 14(12):1613-1624.
-
Off-label closure during CLOSURE study. J Invasive Cardiol. 2012 Nov; 24(11):608-11.
-
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44.
-
High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII. J Heart Lung Transplant. 2009 Aug; 28(8):785-90.
-
Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg. 2007 Jul 06; 2:32.